Clinical Trials · NCT07481747
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Hudson Biotech
- Enrollment
- 2,539
- Start date
- Feb 2026
- Locations
- 1 site, China
- Primary endpoint
- Mean percent change in body weight from randomization